Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Weak profitability ⢠Negative cash flow CYRX has a comfortable balance sheet and low leverage, but recurring operating losses and negative cash flow weaken the investment case despite an apparently cheap trailing valuation.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support holding ⢠Resistance cap Support Level: $14.70â$14.90 Resistance Level: $15.70â$16.10, $16.40â$16.60 CYRX remains in a short-term downtrend, with weak momentum and repeated resistance failures offset only by support near $14.70â$14.90 and a modest bounce to $15.12.
Sentiment & News
Key News Insights: ⢠Revenue growth ⢠EBITDA positive ⢠Outlook reaffirmed Cryoport posted Q2 revenue growth to $49.0M, achieved positive adjusted EBITDA, and reaffirmed its $192Mâ$196M full-year outlook.
AI Summary
CYRX is transitioning from a survival story to an execution story: its strong cash balance reduces dilution risk, but the stock only deserves a durable rerating if revenue growth starts converting into sustained operating profit and free cash flow rather than remaining a volatile, loss-making bounce.
Description
Cryoport, Inc. provides temperature-controlled logistics and related services for life sciences customers across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Its offerings include shipment management software, condition-monitoring and tracking tools, cryogenic transport equipment, and storage and handling services for biological materials. The company serves the biopharma, animal health, and human reproductive medicine markets and was founded in 1999 in Brentwood, Tennessee.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | CYRX | Cryoport, Inc. | Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days. | Closed | +4.4% |